Ambry Genetics Announces Launch of their CancerArray™ Product and Services Utilizing aCGH Technology

ALISO VIEJO, CA – August 31, 2011 – Ambry Genetics today introduces their new CancerArray™ product and services utilizing aCGH technology. The Ambry CancerArray™ is a high resolution exon-focused 180K array offering genome-wide probe coverage with higher probe density coverage in over 400 known cancer-associated genes. The array enhances the resolution in these functionally important cancer regions.

“The CancerArray™ is a novel product for oncology-based researchers who want to detect genome-wide copy number variants with enhanced single-gene resolution in cancer associated regions,” said Ardy Arianpour, Ambry’s Vice President of Business Development. “We expect to see high demand and use of our CancerArray™ due to the increasing amount of translational oncology research being conducted by biotech and pharmaceutical companies and academic research groups.”

The Ambry CancerArray™ is a comprehensive high resolution chromosome analysis approach to detect copy number variants without the need and additional cost for independent traditional karyotyping or single gene deletion/duplication analysis. The Ambry CancerArray™ utilizes aCGH technology to cover the entire genome at an average resolution of 20 kb. The 180K CancerArray™ also offers increased coverage in over 400 known cancer-associated genes to further enhance the resolution in these functionally important regions.

“The enhanced CancerArray™ content is partially based on the Wellcome Trust Sanger Cancer Gene Census,” explained Dr. Anja Kammesheidt, Ambry’s Chief Scientific Officer. “The Ambry CancerArray™ will not only detect large copy number changes, but simultaneously will identify very small aberrations, near the single-exon level, in the most important cancer genes associated with germline and somatic variations.”

The Ambry CancerArray™ is now ready to be ordered and processed for research purposes. For more information on the CancerArray™ and the full line of Ambry’s genomic products and services, please visit our website at .